Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
23 Abril 2024 - 9:30AM
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage
biotechnology company focused on unlocking the broad potential of
RNA medicines to transform human health, today provided an update
on its best-in-class small interfering RNA (siRNA) and RNA editing
platform capabilities.
As part of Wave’s ongoing collaboration with GSK, GSK has
selected its first two programs to advance to development
candidates following achievement of target validation. These
programs utilize Wave’s next generation GalNAc-siRNA format and are
in hepatology. GSK will provide an aggregate initiation payment of
$12 million to Wave for these two oligonucleotide programs. Under
the agreement, GSK can advance up to eight programs leveraging
Wave’s PRISM™ platform and multiple RNA-targeting modalities
(RNA editing, splicing, siRNA, and antisense) with target
validation work ongoing across multiple therapy areas.
“We’ve reached an exciting point in our research collaboration,
as selection of GSK’s first two programs signals the next phase of
our work together to bring transformative RNA medicines to
patients,” said Paul Bolno, MD, MBA, President and Chief Executive
Officer of Wave Life Sciences. “The fact that both programs use our
next generation siRNA format also speaks to its growing potential
within our broader toolkit of RNA-targeting modalities. Beyond
these programs, our collaboration is focusing on all Wave
modalities, including RNA editing. We expect additional
opportunities for payments related to our collaboration in 2024 and
beyond.”
Continued Dr. Bolno, “Our wholly owned INHBE program for obesity
also uses our next generation GalNAc-siRNA format and is on track
to initiate clinical trials in the first quarter of 2025. Emerging
preclinical data support a best-in-class profile for our lead
clinical candidate, including potent and durable silencing, weight
loss with no loss of muscle mass, reduction of visceral fat, and
once-or-twice-yearly dosing.”
Under the terms of the agreement with GSK, Wave leads research
for GSK Collaboration Programs up to investigational new drug
(IND)-enabling studies. GSK Collaboration Programs then transfer to
GSK for IND-enabling studies, clinical development, and
commercialization. In total, Wave is eligible for up to $3.3
billion in potential milestone payments, as well as tiered
royalties on net sales, for GSK Collaboration Programs and WVE-006,
for which GSK has an exclusive global license.
Upcoming Congress PresentationsWave will
highlight its siRNA capability and its leadership in RNA editing at
two upcoming congresses: The ASGCT 27th Annual Meeting on May 7-11,
2024, and TIDES USA on May 14-17, 2024. Presentation details are as
follows:
- ASGCT
- Potent, Durable mRNA Knockdown in Extrahepatic Tissues Using
siRNAs with Novel Phosphoryl Guanidine Backbone Variants (Wei Liu,
PhD, Senior Scientist, Wave Life Sciences)Oral Abstract Session:
Oligonucleotide Therapeutics (link)Friday, May 10, 2024 from
4:30-4:45 PM ET
- Chemical Design of Oligonucleotides That Support Targeted RNA
Editing in the CNS of Non-Human Primates (Christopher Acker, Senior
Scientist, Wave Life Sciences)Poster Session: Epigenetic Editing
and RNA Editing (link)Thursday, May 9, 2024 from 12:00-1:30 PM
ET
- TIDES USA
- Impact of Phosphoryl Guanidine (PN) Variants on siRNA Potency
and Durability in Hepatic and Extrahepatic Tissues (Pachamuthu
Kandasamy, PhD, Vice President Medicinal Chemistry, Wave Life
Sciences)Poster SessionWednesday, May 15, 2024 from 2:30-3:30 PM
ET
- Improving the Potency and Sequence Versatility of RNA Editing
Through Oligonucleotide Chemical Modifications (Jack Godfrey, PhD,
Senior Scientist, Wave Life Sciences)Poster SessionWednesday, May
15, 2024 from 2:30-3:30 PM ET
About Wave Life SciencesWave Life Sciences
(Nasdaq: WVE) is a biotechnology company focused on unlocking the
broad potential of RNA medicines to transform human health. Wave’s
RNA medicines platform, PRISM™, combines multiple modalities,
chemistry innovation and deep insights in human genetics to deliver
scientific breakthroughs that treat both rare and prevalent
disorders. Its toolkit of RNA-targeting modalities includes
editing, splicing, RNA interference and antisense silencing,
providing Wave with unmatched capabilities for designing and
sustainably delivering candidates that optimally address disease
biology. Wave’s diversified pipeline includes clinical programs in
Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and
Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, Wave is leading the
charge toward a world in which human potential is no longer
hindered by the burden of disease. Wave is headquartered in
Cambridge, MA. For more information on Wave’s science, pipeline and
people, please visit www.wavelifesciences.com and follow Wave on X
(formerly Twitter) and LinkedIn.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, our expectations for our next
generation GalNAc-siRNA format and its potential for best-in-class
potency and durability; the anticipated timing of our INHBE
clinical trial; our expectations to earn additional collaboration
payments in 2024 and beyond; the potential for us to earn
substantial additional milestone payments and tiered royalties in
our GSK collaboration; and our plans to highlight our siRNA
capability and our leadership in RNA editing at upcoming
congresses. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release and actual results may
differ materially from those indicated by these forward-looking
statements as a result of these risks, uncertainties and important
factors, including, without limitation, the risks and uncertainties
described in the section entitled “Risk Factors” in Wave’s most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission (SEC), as amended, and in other filings Wave
makes with the SEC from time to time. Wave undertakes no obligation
to update the information contained in this press release to
reflect subsequently occurring events or
circumstances.Investor Contact:Kate Rausch+1
617-949-4827krausch@wavelifesci.com
Media Contact:Alicia Suter+1
617-949-4817asuter@wavelifesci.com
Wave Life Sciences (NASDAQ:WVE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Wave Life Sciences (NASDAQ:WVE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024